Oncology Peer Review On-The-Go: Paolo Tarantino, MD, and Sara Tolaney, MD, Review Data in the Treatment of Breast Cancer at 2022 ASCO


Paolo Tarantino, MD, and Sara M. Tolaney, MD, MPH, spoke with CancerNetwork® about highlights from 2022 ASCO in breast cancer research.

In the inaugural Twitter Spaces edition of the Oncology Peer Review On-The-Go podcast hosted by CancerNetwork®, Paolo Tarantino, MD, a clinical research fellow at Dana-Farber Cancer Institute, and Sara M. Tolaney, MD, MPH, chief of the Division of Breast Oncology and associate director of the Susan F. Smith Center for Women’s Cancer at Dana-Farber as well as an associate professor of medicine at Harvard Medical School, reviewed presentations in breast cancer research from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

During the live event, Tarantino and Tolaney discussed the phase 3 DESTINY-Breast04 trial (NCT03734029), of fam-trastuzumab-nxki (Enhertu) vs chemotherapy for patients with HER2-low, hormone receptor–positive metastatic breast cancer. The co-hosts also reviewed surprising results from phase 3 PALOMA-2 trial (NCT01740427), which failed to show an overall survival benefit with use of palbociclib (Ibrance) plus letrozole in patients with estrogen receptor–positive/HER2-negative advanced breast cancer vs letrozole alone.

Additionally, Tolaney discussed her presentation of the phase 3 monarchE trial (NCT03155997) that explored adjuvant abemaciclib (Verzenio) in patients with hormone receptor–positive, HER2-negative, node-positive high-risk early breast cancer.

Overall, both investigators said they enjoyed coming back to in-person conferences and how they hope the trend of practice-changing trials continues with future conferences.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Related Videos
Administering immunotherapy following surgery in patients with early-stage triple-negative breast cancer does not appear to be as effective as beginning with neoadjuvant treatment, says Peter Schmid, MD, PhD.
Heather A. Parsons, MD, MPH, says she is excited about HER2 as a biomarker and investigating the biology of metastatic breast cancer with a minimally invasive liquid biopsy platform.
Exercise and healthy lifestyles can lower the risk of cancer or the symptoms of cancer treatment despite having genetic dispositions, said Neil M. Iyengar, MD.
The Hispanic Breast Cancer Clinic at Northwestern Memorial Hospital includes a social worker, nurse practitioners, a medical oncologist, a radiation oncologist, and surgeons, says Claudia Tellez, MD.
The goal of creating the Hispanic Breast Cancer Clinic at Northwestern Memorial Hospital is to establish a safe space for Hispanic patients, says Claudia Tellez, MD.
Several factors may contribute to the low Hispanic breast cancer population at Northwestern Memorial Hospital, including a lack of resources and a focus on other disease types.
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Related Content